Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. We tested the role of exercise as an adjuvant to a booster of a COVID-19 vaccine. Immunocompromised patients were immunized after an acute bout of exercise or not. Patients exhibited an excellent immunogenicity in response to the booster dose. Exercise did not add to the vaccine effects on IgG or neutralizing antibodies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897009PMC
http://dx.doi.org/10.1152/japplphysiol.00015.2022DOI Listing

Publication Analysis

Top Keywords

booster dose
20
bout exercise
12
patients spondyloarthritis
12
control group
12
patients
11
exercise
9
booster
9
exercise bout
8
dose inactivated
8
inactivated sars-cov-2
8

Similar Publications

Introduction: Autoimmune thyroiditis (AIT) is a chronic autoimmune disease characterized by lymphocytic infiltration of the thyroid gland and elevated specific antibodies. Its incidence rises annually, yet no standardized animal model fully mimics human AIT. Given unclear pathogenesis and lack of targeted immunotherapies, researchers invest significant time in developing suitable models.

View Article and Find Full Text PDF

Cellular and humoral immunity following two AZD1222 and two booster vaccinations in hemodialysis patients.

J Microbiol Immunol Infect

August 2025

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:

Background: Dialysis patients are vulnerable to SARS-CoV-2 infection and subsequent complications. However, the vaccine-induced immunity, especially against new variants, following two AZD1222 and two booster doses in hemodialysis patients remain largely unknown.

Methods: In this observational cohort study, we monitored immune responses in 127 hemodialysis patients receiving the 3 and 4th vaccinations until three months after the 4th immunization.

View Article and Find Full Text PDF

ObjectivesHistorically, vaccines have been administered in the dorsal interscapular region of cats (the 'scruff' of the neck) owing to easy access to the subcutaneous space. In response to concerns about sarcomas developing at injection sites (feline injection site sarcomas [FISSs]), and a possible association between feline leukaemia virus (FeLV) vaccination and the development of FISS, alternative FeLV vaccination sites such as the distal left hindlimb and tail have been proposed by influential vaccination bodies and various key opinion leaders. There is a dearth of evidence, however, to demonstrate the development of a comparable immune response after FeLV vaccination in these sites.

View Article and Find Full Text PDF

Objectives: Hepatitis B vaccination is recommended for those receiving kidney transplants. When hepatitis B surface antibody (HBsAb) levels remain low, the booster dose of the vaccine should be considered. Some consider that the use of a different product as a booster might be beneficial to the patients, but the effectiveness of such a strategy has not been evaluated.

View Article and Find Full Text PDF

Assessing immunization coverage in Southern togo: implications for perennial malaria chemoprevention delivery.

BMC Public Health

September 2025

Research Institute for Sustainable Development (IRD) EMR 271, University of Bordeaux, National Institute for Health and Medical Research (INSERM), UMR 1219, Bordeaux Population Health Research Centre, Bordeaux, France.

Background: Malaria remains a major health challenge in sub-Saharan Africa, especially for children under five. The World Health Organization (WHO) recommends perennial malaria chemoprevention (PMC) to children in areas of medium to high perennial transmission. In Togo, since 2022, a pilot project has leveraged the Expanded Program on Immunization (EPI) to deliver PMC to children under two years; however, the extent to which PMC achieves its desired outcome may depend on EPI performance.

View Article and Find Full Text PDF